Regenxbio Inc (RGNX)
14.35
0.00 (0.00%)
USD |
NASDAQ |
May 31, 16:00
14.36
0.00 (0.00%)
After-Hours: 20:00
Regenxbio Revenue (TTM): 86.73M for March 31, 2024
Revenue (TTM) Chart
Historical Revenue (TTM) Data
Date | Value |
---|---|
March 31, 2024 | 86.73M |
December 31, 2023 | 90.24M |
September 30, 2023 | 99.37M |
June 30, 2023 | 96.97M |
March 31, 2023 | 109.64M |
December 31, 2022 | 112.72M |
September 30, 2022 | 480.03M |
June 30, 2022 | 484.30M |
March 31, 2022 | 473.68M |
December 31, 2021 | 470.35M |
September 30, 2021 | 93.14M |
June 30, 2021 | 161.28M |
March 31, 2021 | 155.81M |
December 31, 2020 | 154.57M |
September 30, 2020 | 144.89M |
June 30, 2020 | 60.68M |
March 31, 2020 | 51.99M |
December 31, 2019 | 35.23M |
Date | Value |
---|---|
September 30, 2019 | 64.24M |
June 30, 2019 | 54.85M |
March 31, 2019 | 87.00M |
December 31, 2018 | 218.50M |
September 30, 2018 | 179.77M |
June 30, 2018 | 175.80M |
March 31, 2018 | 142.33M |
December 31, 2017 | 10.39M |
September 30, 2017 | 10.05M |
June 30, 2017 | 8.838M |
March 31, 2017 | 4.651M |
December 31, 2016 | 4.589M |
September 30, 2016 | 7.341M |
June 30, 2016 | 8.356M |
March 31, 2016 | 7.344M |
December 31, 2015 | 7.595M |
September 30, 2015 | 4.295M |
June 30, 2015 | 3.638M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (TTM) Range, Past 5 Years
35.23M
Minimum
Dec 2019
484.30M
Maximum
Jun 2022
174.04M
Average
104.51M
Median
Revenue (TTM) Benchmarks
Sarepta Therapeutics Inc | 1.403B |
Pfizer Inc | 55.09B |
PTC Therapeutics Inc | 927.56M |
BridgeBio Pharma Inc | 218.60M |
Edgewise Therapeutics Inc | -- |